Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial

BACKGROUND: Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Keiser, Jennifer, Silué, Kigbafori D., Adiossan, Lukas K., N'Guessan, Nicaise A., Monsan, N'Chou, Utzinger, Jürg, N'Goran, Eliézer K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102459/
https://www.ncbi.nlm.nih.gov/pubmed/25033291
http://dx.doi.org/10.1371/journal.pntd.0002975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102459/
https://www.ncbi.nlm.nih.gov/pubmed/25033291
http://dx.doi.org/10.1371/journal.pntd.0002975

Ejemplares similares